Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Wednesday 27th March 2019 from 11:00 AM to 1:00 PM (GMT).

During this time our website performance may be temporarily affected. We apologise for any inconvenience this might cause and thank you for your patience.


Issue 1, 2019
Previous Article Next Article

Gene expression profile-based drug screen identifies SAHA as a novel treatment for NAFLD

Author affiliations

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. Being part of the metabolic syndrome, NAFLD is characterized by the deposition of triglycerides (TGs) as lipid droplets in the cytoplasm of hepatic cells. Recently, the rapid development of high-throughput genome analysis technologies provided opportunities to screen for new drugs for NAFLD. In this study, we screened for potential drugs based on the gene expression profiles of 73 compounds and identified histone deacetylase (HDAC) inhibitors as a novel treatment for the accumulation of lipids in hepatocytes. In the subsequent analysis and experiments, we discovered that SAHA inhibited the fatty acid and lipid metabolism pathways in hepatic cells and induced a significant deficiency of lipid accumulation in HepG2 and SMMC-7721 cells. Furthermore, SAHA inhibited lipid synthesis in hepatic cells by directly suppressing the expression of DGAT2. Hence, our study provides a novel method to screen for effective drugs for liver diseases and identifies SAHA as a potent treatment for NAFLD.

Graphical abstract: Gene expression profile-based drug screen identifies SAHA as a novel treatment for NAFLD

Back to tab navigation

Supplementary files

Publication details

The article was received on 14 Sep 2018, accepted on 14 Dec 2018 and first published on 03 Jan 2019


Article type: Research Article
DOI: 10.1039/C8MO00214B
Citation: Mol. Omics, 2019,15, 50-58

  •   Request permissions

    Gene expression profile-based drug screen identifies SAHA as a novel treatment for NAFLD

    Z. Cheng, Y. Wen, B. Liang, S. Chen, Y. Liu, Z. Wang, J. Cheng, X. Tang, H. Xin and L. Deng, Mol. Omics, 2019, 15, 50
    DOI: 10.1039/C8MO00214B

Search articles by author

Spotlight

Advertisements